What Has Changed For QuidelOrtho Since Its 60% Fall

QuidelOrtho has not lacked headlines in 2026, from weak respiratory testing demand to policy worries over future diagnostic volumes. Investors who held QuidelOrtho from the start of the year are down 60.0%, including dividends. If you were weighing a fresh position back on 2026-01-01, that outcome is the backdrop. The pressing question now is whether debt reduction plans and any portfolio reshaping can realistically support a different experience from here.

This theme extends beyond QuidelOrtho. See which of 36 healthcare AI stocks may still merit a closer look.

The Argument You Would Have Been Weighing Up On QuidelOrtho

The shares cost US$28.56 at the start of the period, and QuidelOrtho sat between two very different stories about where diagnostic demand and profitability might go next.

On the optimistic side, one narrative saw global expansion and decentralized testing opening a long runway. It suggested a Fair Value of US$40.33, a price implied by assumptions like 2.6% annual revenue growth and profit margins moving from a loss toward 0.6%.

The cautious view centered on debt and cost pressure, with a Fair Value of US$26. This was based on 2.5% annual revenue growth but profit margins only reaching 12.5% and a future P/E of 6.6x.

What The Results Changed For QuidelOrtho

QuidelOrtho’s clearest move was to address its balance sheet by exploring a US$1.5b sale of its point of care unit. This supported the cautious case that focused on debt and cost pressure. Reported Q3 2026 revenue declined to US$618.9m from US$699.9m a year earlier, while the loss narrowed and net margin improved from -104.7% to -8.7%, so profitability targets in the optimistic case remain unproven.

The lesson is simple. When a thesis depends on future margin repair, you check two things quarter by quarter: whether net margin is moving toward the stated level, and whether any asset sales or restructurings are shrinking or reshaping the earnings base that margin will apply to.

What Today's QuidelOrtho Price Already Assumes

QuidelOrtho trades at US$11.52 today, after a 60.0% loss from the start of the year. The analyst consensus Narrative on Simply Wall St places its Fair Value above that level, based on a view that cost cuts and cash generation efforts can reshape the story.

The same Narrative leans on core diagnostics and cash flow rather than respiratory swings. For that higher figure to be reached, a buyer today would need to assume management actually delivers sustained margin and free cash flow improvement on a smaller, refocused business.

"The main priority is management delivering on multi year margin expansion and cash conversion improvements while offsetting regulatory and pricing pressure in China and softer respiratory testing. The current narrative that QuidelOrtho is fairly valued and bullish suggests the share price already reflects both the planned cost savings and growth in core diagnostics, along with the risks from China, respiratory demand, and leverage."

One Narrative disagrees with today's price. → See where this Narrative says QuidelOrtho should trade

Which Company Could Surprise You Next?

This company's disappointment is already part of the story. Your next idea could come from looking where the price and the possibilities still seem far apart. Here are three companies priced below our estimates.

• Company 1 - 31% below our estimate - benefits as scarce offshore support vessels gain pricing power on extended contracts.
• Company 2 - 23% below our estimate - shifts buyers toward higher margin stormwater solutions and recycled products using dedicated trucking.
• Company 3 - 35% below our estimate - rides expansion in data center projects that has significantly increased its contracted backlog.

Those are three of them. See all 35 potentially undervalued companies →

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com